VIDEO: ‘No new safety events’ for abrocitinib in atopic dermatitis

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase 1 inhibitor abrocitinib from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed a study that provided predictive data on how doses should be adjusted, in addition to an updated safety and efficacy analysis.

“What it showed us was that all the confidence we’ve had in short-term data is really mirrored in the long-term data, and in particular, no new safety events, which has really enjoyed our years for [Janus kinase] inhibitors,” Chovatiya said.